Long-term Clinical Results of Laparoscopic Splenectomy for Surgical Disease of the Spleen: Recent Outcomes.
10.7602/jmis.2013.16.4.91
- Author:
Jeong Eun SEO
1
;
Seog Ki MIN
;
Hyeon Kook LEE
Author Information
1. Department of Surgery, School of Medicine, Ewha Womans University, Seoul, Korea. mp9666@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Laparoscopic splenectomy;
Hematologic diseases;
Immune thrombocytopenic purpura
- MeSH:
Diagnosis;
Follow-Up Studies;
Hematologic Diseases;
Humans;
Length of Stay;
Methods;
Mortality;
Operative Time;
Purpura, Thrombocytopenic, Idiopathic;
Recurrence;
Retrospective Studies;
Spleen*;
Splenectomy*;
Splenomegaly
- From:Journal of Minimally Invasive Surgery
2013;16(4):91-97
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Laparoscopic splenectomy (LS) is one method for treatment of various diseases of the spleen, especially hematological conditions. However, few recent long-term follow-up results have been reported. The purpose of this study is to evaluate the outcome of patients in a single institution who recently underwent LS and to analyze their long-term follow-up results. METHODS: Of 366 splenectomies, this study was conducted as a retrospective review of 52 patients who underwent LS for treatm ent of hematological or primary diseases of the spleen from January 1998 to October 2011. The data included age, sex, pathological diagnosis, operative time, postoperative hospital stay, rate to open conversion, perioperative transfusion, morbidity, mortality, and relapse. We analyzed outcomes of variable results through long-term follow-up. RESULTS: The mean follow-up period was 84 months (range, 4~147 months). The most common indication for LS was immune thrombocytopenic purpura (ITP). The median postoperative hospital stay was eight days (range, 3~28 days). Mean operative time was 203 minutes (range, 115~475 minutes). Two patients underwent open conversion. Thirty eight patients received perioperative transfusions. The mean spleen weight was 294.9 g (range, 31~2,564 g). The overall morbidity rate was 5.8% and one patient experienced relapse. Of the 28 patients with ITP, 89.3% responded to LS. CONCLUSION: LS should be one of the best treatment options regardless of splenomegaly and spleen-associated diseases. In particular, for patients with ITP, LS has shown very effective long-term follow-up results. Therefore, LS should be more actively considered as an early treatment option in surgical disease of the spleen, such as ITP.
